Advanced Filters
noise

Found 706 clinical trials

Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction

Although anti-retroviral therapy (ART) enhances life expectancy and overall quality of life (QoL), HIV-infected individuals are increasingly vulnerable to non-AIDS-related diseases including HIV-associated neurocognitive disorders (HAND). Inflammation is a primary mechanism in the pathogenesis of HAND and tobacco use may further exacerbate inflammation. Conversely, nicotine alone has anti-inflammatory effects suggesting …

40 years and older
All
Phase N/A

Genetics and Heart Health after Cancer Therapy

The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease. We plan to enroll 100 BRCA1/2 mutation carriers who have been treated for …

99 years and younger
All

Neural Basis Of Eating Behavior In Abstinent Smokers

The purpose of this study is to evaluate brain responses to food in smokers during a short smoking abstinence period compared to smoking as usual.

18-65 years
All
Phase N/A

ConsCIOUS2: A Prospective Study of the Isolated Forearm Technique Commands Long-term Sequelae and Electroencephalograph Correlates Following Laryngoscopy and Intubation in patients 18 - 40 years of age

This a multi-center prospective cohort study of a series of commands surveying responsiveness following laryngoscopy and intubation. Clinical care will not be controlled and will be left to local policy. We will also collect routinely recorded clinical data to frame the observations about IFT responsiveness (please see list below and …

99 years and younger
All

A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS)

The purpose of this study is to evaluate different treatment options for patients with skin vasculitis (also named cutaneous vasculitis). Patients with isolated cutaneous small vessel vasculitis, medium-sized vessel vasculitis (polyarteritis nodosa), or IgA vasculitis (Henoch-Schönlein purpura) can join this study. The frequently used treatments for skin vasculitis are colchicine, …

99 years and younger
All

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

This study employs a multi-center approach to evaluate cutaneous vasculitis across several forms of idiopathic vasculitis. Patients with cutaneous manifestations of vasculitis will be evaluated by teams of primary vasculitis care providers and Dermatologists in order to facilitate optimal selection of patients and sampling of lesions. A punch skin biopsy …

99 years and younger
All

A DOUBLE BLIND RANDOMIZED VEHICLE CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION 0.5% FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS T-CELL LYMPHOMA (CTCL

This application is a request to execute a reliance agreement with Chesapeake an external IRB This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF), which is a type …

99 years and younger
All
Phase 3

Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

The purpose of this study is to compare the effect of the investigational drug, mavacamten, (MYK-461), to a placebo (an inactive substance) in patients with Non-obstructive Hypertrophic Cardiomyopathy (nHCM).

18-99 years
All
Phase 2

A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter, international, parallel-group study to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo (1:1) in participants with symptomatic oHCM. Approximately 220 participants will be enrolled. This includes ~80 participants (~40 per treatment group) who consent to participate in a …

99 years and younger
All
Phase 3

Simplify language using AI